
Fenebrutinib by Genentech Marks Major Breakthrough in Treating Primary Progressive Multiple Sclerosis
Genentech’s Fenebrutinib Is the First Investigational Medicine in Over a Decade That Reduces Disability Progression in Primary Progressive Multiple Sclerosis (PPMS) Genentech, a member of the Roche Group announced today…












